## Clinical Diagnosis This patient presents with **systolic heart failure (HFrEF)** with LVEF 35% and classic signs of decompensation: orthopnea, PND, elevated JVP, and pulmonary crackles. ## Pathophysiology of HFrEF Management **Key Point:** The cornerstone of HFrEF therapy is the **ACE inhibitor (or ARB) + beta-blocker + diuretic** triad, with aldosterone antagonists added in selected cases. ## Guideline-Based Approach | Drug Class | Role in HFrEF | Mechanism | |---|---|---| | **ACE-I / ARB** | First-line, mortality reduction | Reduces afterload, prevents remodeling | | **Beta-blocker** | First-line, mortality reduction | Reduces sympathetic drive, improves contractility | | **Loop diuretic** | Symptom relief | Reduces pulmonary/systemic congestion | | **Aldosterone antagonist** | Add if LVEF ≤40% + symptoms | Reduces fibrosis, mortality benefit | **High-Yield:** The sequence is **ACE-I + beta-blocker FIRST**, then add diuretics for congestion, then consider aldosterone antagonist. ## Why Option 0 Is Correct 1. **Furosemide 40 mg daily** — addresses acute congestion (crackles, elevated JVP) 2. **Lisinopril 5 mg daily** — ACE-I; reduces afterload and prevents LV remodeling; mortality benefit in HFrEF 3. **Carvedilol 3.125 mg BD** — beta-blocker; reduces mortality and hospitalizations in systolic HF This combination follows the **ESC/ACC/AHA guideline hierarchy** for HFrEF. **Clinical Pearl:** Start ACE-I and beta-blocker at low doses and uptitrate over weeks; diuretics are titrated to symptom relief, not fixed doses. ## Why Coronary Angiography Is Not Immediate While ischemic cardiomyopathy is common, **acute decompensation must be stabilized first**. Angiography is indicated if there is evidence of acute ischemia (troponin elevation, dynamic ECG changes) or post-stabilization risk stratification — not as the first step.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.